ALLOGENEIC BONE MARROW TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY

异体骨髓移植治疗血液恶性肿瘤

• 批准号: 3806744
• 负责人: STEPHEN J FORMAN
• 金额: --
• 依托单位: CITY OF HOPE NATIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3806744
• 关键词: acute lymphocytic leukemia; bone marrow transplantation; chronic myelogenous leukemia; clinical trials; cyclophosphamide; cyclosporines; cytomegalovirus; data collection; etoposide; graft versus host disease; homologous transplantation; human subject; human therapy evaluation; immunization; immunosuppressive; leukemia; longitudinal human study; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; opportunistic infections; prednisone; statistics /biometry; thalidomide; viral pneumonia; whole body irradiation dosage

This project deals with seven important areas of allogeneic bone marrow transplantation for hematologic malignancy: 1. We propose to conduct a prospective collaborative trial comparing high dose chemoradiotherapy and marrow transplantation to chemotherapy for patients with acute lymphoblastic leukemia during first complete remission. 2. We will perform a phase II study to decrease the relapse rate in patients with leukemia by the addition of cyclophosphamide to the combination of FTBI and VP-16 (acute non-lymphoblastic leukemia (ANLL) in first complete remission, chronic myelogenous leukemia (CML) in chronic phase, acute lymphoblastic leukemia (ALL) and acute non-lymphocyte leukemia not in first remission, chronic myelogenous leukemia not in chronic phase). 3. We will explore the effectiveness of a new preparatory regimen of FTBI, VP-16 and cyclophosphamide in patients receiving matched unrelated transplants or partially matched related transplants. 4. We will also study methods of preventing cytomegalovirus pneumonia by altering the natural history of HCMV infection after allogeneic bone marrow transplantation. 5. We will determine the effectiveness of a new anti-graft-versus-host disease regimen of cyclosporin, prednisone and xomazyme in patients receiving bone marrow allografts from partially matched unrelated or related donors. 6. We will determine the role of thalidomide in the prevention of chronic graft-versus-host disease after allogeneic bone marrow transplantation. 7. We will conduct a randomized trial to determine the efficacy of methotrexate, cyclosporin and prednisone compared to xomazyme, cyclosporin and prednisone for patients receiving matched sibling allografts.

该项目处理同种异体骨髓的七个重要领域 血液系统恶性肿瘤的移植： 1。我们建议进行一项前瞻性协作试验，比较高 剂量化学放疗和骨髓移植到化学疗法的 在第一次完全缓解期间患有急性淋巴细胞白血病的患者。 2。我们将进行II期研究以降低复发率 通过在 FTBI和VP-16（急性非蛋白白血病（ANLL）的组合 首先完全缓解，慢性慢性骨髓性白血病（CML） 阶段，急性淋巴细胞白血病（全部）和急性非淋巴细胞白血病 并非首次缓解，慢性骨髓性白血病不在慢性期）。 3。我们将探讨FTBI的新预备方案的有效性， 接受匹配的无关的患者的VP-16和环磷酰胺 移植或部分匹配的相关移植。 4。我们还将研究预防巨细胞病毒肺炎的方法 改变同种异体骨髓后HCMV感染的自然病史 移植。 5。我们将确定新的反植物交流宿主的有效性 患者环孢菌素，泼尼松和Xomazyme的疾病方案 从部分匹配的无关或 相关捐助者。 6。我们将确定沙利度胺在预防慢性中的作用 同种异体骨髓移植后移植物与宿主疾病。 7。我们将进行一项随机试验以确定 甲氨蝶呤，环孢菌素和泼尼松与Xomazyme，环孢菌素相比 和接受匹配兄弟姐妹同种异体移植的患者的泼尼松。